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Abstract
Background: Chronic Migraine (CM) is a disabling condition, worsened when associated with Medication Overuse
(MO). Mindfulness is an emerging technique, effective in different pain conditions, but it has yet to be explored for
CM-MO. We report the results of a study assessing a one-year course of patients’ status, with the hypothesis that the
effectiveness of a mindfulness-based approach would be similar to that of conventional prophylactic treatments.
Methods: Patients with CM-MO (code 1.3 and 8.2 of the International Classification of Headache Disorders-3Beta)
completed a withdrawal program in a day hospital setting. After withdrawal, patients were either treated
with Prophylactic Medications (Med-Group), or participated in a Mindfulness-based Training (MT-Group).
MT consisted of 6 weekly sessions of guided mindfulness, with patients invited to practice 7–10 min per
day. Headache diaries, the headache impact test (HIT-6), the migraine disability assessment (MIDAS), state
and trait anxiety (STAI Y1-Y2), and the Beck Depression Inventory (BDI) were administered before withdrawal
and at each follow-up (3, 6, 12 after withdrawal) to patients from both groups. Outcome variables were
analyzed in separate two-way mixed ANOVAs (Group: Mindfulness vs. Pharmacology x Time: Baseline, 3-, 6-,
vs. 12-month follow-up).
Results: A total of 44 patients participated in the study, with the average age being 44.5, average headache frequency/
month was 20.5, and average monthly medication intake was 18.4 pills. Data revealed a similar improvement over time
in both groups for Headache Frequency (approximately 6–8 days reduction), use of Medication (approximately 7 intakes
reduction), MIDAS, HIT-6 (but only for the MED-Group), and BDI; no changes on state and trait anxiety were found. Both
groups revealed significant and equivalent improvement with respect to what has become a classical endpoint in this
area of research, i.e. 50% or more reduction of headaches compared to baseline, and the majority of patients in each
condition no longer satisfied current criteria for CM.
Conclusions: Taken as a whole, our results suggest that the longitudinal course of patients in the MT-Group, that were
not prescribed medical prophylaxis, was substantially similar to that of patients who were administered
medical prophylaxis.
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Background
Headache disorders are common disabling conditions
that, in the last Global Burden of Disease study, were
rated as the sixth cause of disability [1]. Further, medica-
tion overuse headache was rated as the 18th and, among
those aged under 50, migraine was rated as the third
cause of disability [2]. Chronic Migraine (CM), is con-
strued as a negative evolution of episodic migraine,
based on the findings that approximately 2.5% of epi-
sodic migraineurs progress to CM each year [3], with a
prevalence of approximately 2% [3, 4]. CM is diagnosed
when headache episodes occur more than 15 days/
month (with at least 8 displaying migraine headache fea-
tures) for more than three months [5], and is frequently
associated with overuse of acute medications. This has
been hypothesized to be one of the chief factors contrib-
uting to migraine chronification [6, 7] and, when overuse
of medicine reaches a level to warrant a diagnosis of
Medication Overuse (MO), it further complicates CM
making it particularly difficult to manage. Chronic
Migraine associated with Medication Overuse (CM-MO)
is diagnosed when the intake of headache medications
for headache episodes is greater than 15 days/month for
simple analgesics, or exceeds 10 days/month for triptans,
opioids, ergotamine or combinations of certain drugs
[5]. A recent review of the literature evidenced that anal-
gesics and opioids are associated with a higher risk of
developing MO and the authors concluded that the so-
called “migraine-specific” treatments, namely triptans
and ergots, should be preferred as they are less fre-
quently associated with development of overuse and dis-
ease chronification [8].
Patients with CM-MO present therapeutic challenges
and require multidisciplinary care, including pharmaco-
logical and non-pharmacological therapeutic approaches
[9]. Various pharmacological therapies have more re-
cently been developed to help these patients better
manage their condition [10–13], but symptom resolution
is not always optimal and up to one third of patients
relapse by 12 months [14–16]. Medication withdrawal
is strongly recommended and its use can be viewed
as a “reset” that then affords patients a greater likeli-
hood of positively responding to appropriate prophy-
lactics [13, 17, 18]. It is most helpful when patients
are provided education and support about proper use
of medications and taught strategies for avoiding re-
lapse [19]. Studies have shown that such approaches
can produce significant improvements that endure for
extended periods, up to 5 years [20, 21].
CM-MO results in pervasive negative consequences,
where personal suffering is accompanied by reduced
quality of life and disability, and decreased abilities to
participate in daily work and/or family activities,
which often results in increasing symptoms of
depression [12, 22–24]. Clinicians and researchers
working in the field of headache disorders are becom-
ing increasingly aware of the consequences of this
condition, the resultant need for a multifactorial ap-
proach and treatment [25]. The joint use of pharma-
cological and non-pharmacological techniques has
been shown to improve the health status of migraine
patients and to enhance clinical outcomes by teaching
and reinforcing patients to implement alternative pro-
cedures for addressing and coping with headache at-
tacks [9, 26–30].
Among the wide array of available non-pharmacological
treatments, mindfulness has been recently included in re-
habilitation programs for chronic pain conditions [31–36].
Its efficacy has been addressed in a recent review of the
psychological therapies in the neurorehabilitation of pain
syndromes [37], where it has been judged as effective
(Grade Level A) for chronic pain syndromes with hetero-
geneous physiopathology, exclusive of headache disorders.
However when this review was prepared researchers had
only begun to explore the utility of mindfulness for head-
ache, so no firm recommendations could be made. The
success with other pain conditions, however, has spurred
researchers in the field of headache to increasingly turn
their attention to mindfulness training as another viable
alternative approach for supplementing patient care. The
main goal of this approach is to increase patient awareness
of their pain and improve their abilities to manage head-
ache before resorting to their former medications [38–45].
As concluded in two recent reviews on the use of
mindfulness-based approaches in headache disorders
[46, 47], this kind of approach seems promising. In
brief, literature findings [40–45] suggest that various
mindfulness-based approaches may be helpful for
headache sufferers, and that it may be of value also
for those with CM-MO. However, the available stud-
ies are limited by an inadequate consideration of
some of the most important endpoints in chronic
headache research, namely the frequency of headache
and the consumption of medications for acute head-
aches management. Further, other meaningful indica-
tors of effectiveness, such as pain intensity, headache
duration, disability, quality of life and some mental
health-related variables, such as stress, anxiety, pain
acceptance or self-efficacy, have yet to be fully ex-
plored. A second relevant shortcoming is the limited
duration of follow-up reported in these studies, which
has ranged between 3 weeks and 3 months. Finally,
what is not clear is the ability of a mindfulness-based
approach by itself to impact key primary as well as
secondary migraine headache parameters, as well as
promote reductions in consumption of acute medica-
tions. Two research areas, thus, warrant further atten-
tion: first, identifying optimal components and
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delivery schedules, by adequately specifying the inter-
vention protocols; second, conducting rigorous con-
trolled trials that assess the durability of effects over
extended time periods, with appropriate control con-
ditions and a clear specification of primary and sec-
ondary outcomes.
As a way to begin to address these uncertainties we
conducted an exploratory clinical trial, one that com-
pared conventional prophylactic pharmacological treat-
ment alone to a mindfulness-based treatment alone for
patients diagnosed with CM-MO and incorporated a
more extended follow-up period. We carefully moni-
tored the clinical course of these patients after all had
undergone a structured withdrawal, with the hypothesis
that the mindfulness-based approach would be similar in
effectiveness when compared to conventional prophylac-
tic treatment, for reducing headache frequency, con-
sumption of acute medications, headache impact,
symptoms of depression, and of anxiety.
Methods
Participants
Eligible patients were those diagnosed with CM-MO –
i.e. code 1.3 and associated medication overuse, follow-
ing the international criteria included in point 8.2 of the
International Classification of Headache Disorder III edi-
tion, beta version (ICHD-3-beta) [5] – who presented
consecutively for treatment at the Headache Centre of
the Neurological Institute C. Besta of Milan, Italy, be-
tween February 2014 and June 2015. These patients were
aged between 18 and 65 years and had a history of CM
lasting for at least ten years that was associated with
overuse of Triptans and non-steroidal anti-inflammatory
drugs (NSAIDs) for a minimum of the past five years.
Patients with comorbid major psychiatric disorders,
namely psychotic disorders and personality disorders,
determined on the basis of clinical history and psychi-
atric evaluation, or pregnancy were excluded.
Procedures
All patients were first admitted to our out-patient day
hospital service, where they participated in a 5-day
structured medication withdrawal program that
utilized intravenous therapy, including steroids and
ademetionine [28, 48]. During withdrawal, patients
were instructed to avoid the use of medications to
manage any acute pain attacks. Upon completion of
the structured medication withdrawal, all patients
were encouraged to increase their physical activity
and perform aerobic exercises, for 45 min twice per
week, maintain a suitable level of hydration, and
strive to consume 3 meals each day on a regular basis
(emphasizing breakfast). Prior to discharge from the
day treatment program, patients were informed of the
possibility to participate in a new clinical trial, in
which they could receive “medication alone” or
“mindfulness training alone” (Med-Group or MT-
Group).
Patients participating in the Med-Group received only
prophylactic medications. The preventive compound
was chosen on the basis of clinical history and medical
comorbidities [49–52], such as done in routine care.
Patients included in the MT-group, participated in a
series of mindfulness training sessions and were not pre-
scribed any form of prophylaxis. The mindfulness proto-
col we used was implemented on the basis of the
Mindfulness-Based-Stress-Reduction MBSR program
(MBSR) by Jon Zabat-Zinn [53]. Together with a close
variant – the mindfulness-based cognitive therapy
(MBCT) [54] – this is the most largely applied for vari-
ous forms of recurrent pain [46], which we partially
modified with regard to the frequency and the duration
of sessions to increase the likelihood of adherence to
treatment by patients. Training was provided in small
groups (5–6 patients), that met in a relaxed and quiet
room every consecutive Monday for 6 weekly sessions,
each of about 45 min duration. All sessions were guided
by an experienced neurologist trained in mindfulness
practice. The order in which the different techniques
and phases were administered– with the due caution
and flexibility – was as follows. First, patients were pro-
vided a detailed explanation about the treatment proto-
col; i.e. what it is and what it is not, and in which
clinical conditions it may be of most value. Second,
patients were trained to assume a relaxed position that
promoted good and regular breathing, while their eyes
remained closed, with them maintaining a relaxed sitting
position. Third, during the first meditations (approxi-
mately up to the second/third session), patients were
invited to focus on attention on their breathing, on the
present and on silence to enhance awareness of current
mind and body sensations. Fourth, once patients learned
to focus on the present, they erre requested to enhance
awareness of their thoughts (third and fourth session),
accepting them in a non-judgmental way. Fifth, in the
last sessions (generally the last two), when patients had
gathered higher awareness of their thoughts and the
capacity to accept them, they were invited to preserve
themselves from interfering thoughts, and to focus on
the present and on the sensations they received from
their bodies. When distractions occurred, patients were
informed to resume attention to breathing and body
awareness and observe the interfering content in a non-
judgmental way [55]. Finally patients were encouraged
to supplement their training with regular home self-
practice, of 7–10 min per day (an amount typically
recommended in studies of this type). The importance
of practicing this form of meditation in an effortless
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manner was pointed out. Unlike prior investigations
[41], we purposely limited the number of techniques to
promote mastery of a few (versus exposure to numerous
modalities where patients may be unable to master any
to a meaningful degree) and keep time demands low and
similar to that for pharmacological treatment.
This was an exploratory study, conducted in a working
clinic that draws patients from a large coverage area,
and the neurologist who guided the mindfulness sessions
was one of the authors (LG), who had undergone exten-
sive training in mindfulness at the Association for Medi-
tation and Awareness under the supervision of Prof.
Corrado Pensa. In this clinical setting it was not possible
to implement random assignment, due to limited
resources in terms of personnel and space. Another bar-
rier lies in patients’ provenance and past history: in fact,
our center is a high-level specialty one, and patients
seeking treatment come from all over the country, with
some of them being followed-up for many years, thus
making it difficult to enroll patients in a way that is
strictly consistent with the requirements of a RCT.
Therefore, certain aspects were not blinded: in particu-
lar, the investigators knew which patients attended
mindfulness sessions and which not, as those that did
not attend the sessions needed to be supervised with
regard to eventual side effects of prophylactic medica-
tions. Participation was, thus, on a voluntary basis, with
patients self-selecting their preferred treatment condi-
tion. Patients opting for mindfulness training alone were
informed of the importance of being available to attend
weekly sessions on a consistent basis upon discharge.
Patients unable to commit to the stated schedule were
invited to participate in the medical prophylaxis alone
condition. Follow-up evaluations were carried out by
another neurologist (DD) to limit possible source of bias
with clinical outcomes, and questionnaire completion
was supervised by a psychologist (ES). Given these con-
siderations we view this investigation as more along the
lines of an effectiveness trial (versus an efficacy trial)
[56]. The consequence of this is that our results have to
be taken as preliminary and the efficacy has to be tested
in future randomized trials.
The study was approved by the Institute’s Ethical
Committee and written informed consent was obtained
from each patient prior to enrollment in the study
protocol. Follow-up assessments were conducted at 3, 6
and 12 months for all available patients. During this
period, patients were instructed to continue their prior
treatments. Patients in both groups were encouraged to
restrict use of acute medications to headaches judged to
be very disabling, operationally defined as a pain inten-
sity rated as 8 or greater on a 0–10 (no pain – pain as
bad as it could be). Patients were instructed to take
Eletriptan (40 mg) and/or Almotriptan (12.5 mg) as the
first-line treatment, and indomethacin (50 mg) as the
second line; with regard to other NSAIDs, they were
urged to take those medications that had already proved
to be effective. Finally, in any case, they were strongly
recommended to avoid opioids to the extent possible.
Measures
Headache diaries [25], completed on a daily basis, pro-
vided the primary measure of outcome, i.e., headache
frequency, and the consumption of acute medications
(NSAIDs and triptans). The amount of single intakes
was recorded, irrespective of the kind of medication.
The Headache Impact Test (HIT-6) [57] is a 6-item
scale that measures lost time in 3 domains and other
areas of impact (e.g., pain severity, fatigue, and mood),
based on patient recall for the immediate past 4 weeks.
Each item is rated on a scale ranging from “never” to
“always.” Total scores range from 36 to 78 with higher
scores indicating greater impact: scores ≥ 60 are indica-
tive of a severe impact.
The Migraine Disability Assessment (MIDAS) [58] is
the most widely used measure of disability in headache
research and we included it to facilitate comparisons
with prior research. It is composed of 7 questions, all
referenced to the preceding 3 months. The first 5
inquire about the number of days during which head-
ache presence disrupted (partially or totally) paid and
school work, household work, and leisure/family/social
duties. Summing these individual values yields a total
disability score, which correspond to four severity level:
0–5, little or no disability; 6–10, mild disability; 11–20,
moderate disability; 21 or above, severe disability. The
remaining two items address the overall headache fre-
quency and average pain intensity, measured on a 0–10
scale. As headache frequency and intensity were pro-
spectively obtained from daily diaries, and the validity of
headache data recalled over three months is question-
able [59], we elected to not report these data here.
Beck Depression Inventory (BDI) [60]. We used the
13-item version, which asks participants to rate the
extent to which they are experiencing each of the 13
common symptoms of depression included. Items are
rated on a scale from 0 to 3 (where 3 represents the
highest severity), with the maximum score being 39.
When used as a screening device, a cut-off score of
9/10 seems best suited for indicating the presence/ab-
sence of depression [61].
The State-Trait Anxiety Inventory (STAI) Y1 and Y2
[62] is composed of two sections, each containing 20
items, that address state and trait anxiety, i.e., the transi-
tory feelings that respondents experience in the moment
in which they complete the questionnaire vs. the rela-
tively stable and enduring personal features reflective of
a predisposition to anxiety. Raw scores range between
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20 and 80 for each scale, with higher scores indicating
higher anxiety levels. The raw scores can be transformed
into norm-based T-Scores (mean 50, SD 10) to enable
comparability across gender and age groups [63].
Data analyses
Mean baseline values for all demographic and dependent
variables for the 2 treatment conditions were compared
by t-tests. The primary and secondary outcome variables
were analyzed in separate two-way mixed ANOVAs
(Group: Mindfulness vs. Pharmacology x Time: Baseline,
3-, 6-, vs. 12-month follow-up), followed by post-hoc
tests, with appropriate adjustments made when signifi-
cant effects were obtained in order to guard against in-
flation of the familywise error rate. Partial eta squared
(η2p) values were calculated for all significant findings,
conservatively interpreting them as small (.01–.08),
medium (.09–.24), and large (≥.25).
We additionally evaluated clinical significance by
determining the percentage of patients that, compared
to baseline evaluation, achieved a 50% or greater re-
duction in migraine frequency and the percentage of
patients who no longer met the diagnostic criteria for
CM at each of the three follow-up evaluations. We
then compared the ratios between the two groups of
patient (MT-Group and Med-Group), for each of
these 2 additional measures, at each time-point using
Chi-Squared analyses. The p-value for significance for
all tests was set at .05.
Results
Fifty patients met inclusion criteria during the study
period, but six declined to participate due to lack of time
or interest. Forty-four patients were therefore enrolled
in this trial, 22 in each condition. In the Med-Group,
five patients received valproate, eight botulinum toxin,
five pizotifen, one amitriptyline, two received a
combination of beta blockers and amitriptyline and one
was given beta blockers and valproate. Table 1 reports
the mean baseline values for all enrolled patients, col-
lectively and by group assignment, along with current
age and age at onset of headache. No differences
were found between the 2 groups for any measures
(the same was true when comparing baseline values
for those who completed the trial; n = 39 versus
those who did not, n = 3). At baseline, a similar per-
centage of patients were overusing triptans: 8 of 22
patients (36.4%) in the Med-Group and 6 of 22 patients
(27.3%) in the MT-Group (χ 2(1) = 0.42, p = .52). The 2
groups did differ with respect to overuse of NSAIDS: 22
of 22 (100%) for Med-Group vs. 18 of 22 for MT-Group
(χ 2(1) = 4.40, p = .04).
Figure 1 shows the flow of patients in each of the two
groups: complete follow-up data at 12 months was avail-
able for 19 patients in the Med-Group and for 20 in the
MT-Group.
Primary and secondary outcomes
Mean values for all measures at all time points are re-
ported for patients who completed the entire trial (see
Table 2). Four of the seven separate mixed within-
between subjects ANOVAs revealed significance only for
the main effect of time— Headache Frequency, Medica-
tion intake, MIDAS, and BDI-13 (see Table 3). Analysis
of the HIT-6 data revealed not only a main effect for
time, but also for the interaction of time and group.
Neither analysis for STAI-S or STAI-T revealed any
significant effects (so these variables are not discussed
further here). Pair wise post-hoc comparisons with
Bonferroni corrections revealed all 3 follow-up points as
significantly improved with respect to baseline values,
but no differences among the 3 follow-up periods, for
Headache Frequency, Medication intake, and BDI-13.
MIDAS scores were significantly different from baseline
Table 1 Mean (and SD) baseline values for all measures for patients who began the trial, all 44 combined and separately for








M SD M SD M SD
Age 44.5 9.2 45.6 9.3 43.5 9.2 0.75 .457
Age at Onset 20.4 9.0 21.5 10.5 19.3 7.3 0.80 .428
Headache frequency/month 20.5 7.9 19.2 7.8 21.9 7.8 -1.14 .263
Monthly medication intake 18.4 6.5 18.0 6.4 18.8 6.7 -0.41 .681
HIT 66.3 5.2 65.5 5.5 67.1 4.9 -1.05 .301
MIDAS 73.1 39.9 65.3 41.4 81.0 37.6 -1.32 .194
BDI-13 13.3 6.1 13.1 5.8 13.6 6.6 -0.32 .754
STAI-S 48.2 7.3 47.1 6.6 49.4 7.9 -1.06 .297
STAI-T 52.3 9.6 52.1 9.3 52.5 10.0 -0.13 .901
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for the 3- and 6-month follow-up, but not for the 12-
month follow-up (see Table 4). Figure 2 graphically pre-
sents the outcomes for headache frequency and con-
sumption of medication for management of acute
headaches over the 12-month follow-up period.
To investigate the source of the significant interaction
effect for the HIT-6, we conducted all pairwise
comparisons for all time points for each group separately
(see Table 5 and Fig. 3). Pairwise comparisons, with
Sidak correction, revealed no differences between any
time points for the MF-Group. For the MED-Group the
3-month and 12-month values were significantly re-
duced when compared to baseline. No other differences
emerged.
Fig. 1 Flowchart of the study
Table 2 Mean values and SD’s for mindfulness (MT-Group) and pharmacology (MED-Group) at each measurement period
MT-Group Med-Group
Baseline 3-MO 6-MO 12-MO Baseline 3-MO 6-MO 12-MO
Headaches Frequency 18.5 ± 7.2 8.3 ± 3.5 10.4 ± 6.9 12.4 ± 8.5 18.5 ± 7.2 8.9 ± 8.0 11.4 ± 8.0 10.4 ± 7.2
Medications intake 17.7 ± 5.9 8.1 ± 4.6 8.9 ± 4.2 10.3 ± 5.4 15.4 ± 4.4 8.8 ± 8.4 11.0 ± 7.6 8.6 ± 4.8
HIT-6 65.3 ± 5.7 62.0 ± 5.7 60.7 ± 10.8 64.5 ± 7.0 66.9 ± 5.2 60.7 ± 7.7 62.6 ± 6.3 61.5 ± 4.8
MIDAS 65.4 ± 43.5 39.0 ± 36.7 41.5 ± 51.7 53.7 ± 52.6 82.9 ± 40.0 26.7 ± 23.5 38.8 ± 25.4 51.5 ± 50.2
BDI-13 13.4 ± 5.9 9.0 ± 6.3 9.0 ± 5.3 10.3 ± 6.8 13.3 ± 6.8 6.2 ± 6.3 8.0 ± 5.9 7.6 ± 6.4
STAI-T 52.3 ± 9.8 48.6 ± 8.4 48.6 ± 7.7 50.9 ± 9.5 52.8 ± 10.2 48.5 ± 9.4 51.3 ± 9.9 48.4 ± 9.6
STAI-S 47.0 ± 6.8 45.4 ± 6.4 45.5 ± 6.9 49.9 ± 9.3 49.6 ± 7.8 47.2 ± 6.1 48.3 ± 10.7 48.6 ± 8.7
N = 19 for MT-Group and N = 20 for MED-Group
Note. Values are expressed as means ± SD
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Percent improvement and percent of patients no longer
meeting criteria for CM
Table 6 reports the percentage of patients showing 50%
or more reduction of headaches compared to baseline
and of patients no longer meeting criteria for CM for
each of the time-points. For both of the clinical end-
points, there were no differences between patients in the
MT-Group and those in the Med-Group. With regard to
the percent improvement variable, the trend had a U-
shaped curve in both groups, while the trend had a J-
shaped curve with regard to the number of patients no
longer meeting the criteria for CM.
Discussion
Our preliminary data show that both groups of patients,
treated with only a single, non-combination interven-
tion—conventional pharmacological approach only ver-
sus a mindfulness-based approach only—revealed
significant decreases in number of monthly headache
days, monthly consumption of medication for acute
headache management, MIDAS, and depressive symp-
toms up to 12-months follow-up. The change in mean
BDI-13 scores (collapsing across groups), appears to be
of clinical significance, as the baseline values, which fell
into the stringent range (13/14) for tentatively identify-
ing moderate to severe clinical depression, had by 12
months fallen overall within the lowest end of the range
suggesting the possible presence of moderate/severe de-
pression (9/10). Although MIDAS scores decreased from
baseline by 28.8% at 12 months, the mean score at this
time point (averaged across both conditions) continued
to fall within the highest severity grade Level (IV). Head-
ache impact was reduced to a statistically significant de-
gree at 3- and 12-month follow-up, but only for the
MED-Group. It is important to point out that at all time
points, neither group revealed clinically meaningful re-
ductions on this measure because means continued to
fall within the highest severity category for this scale (all
means ≥ 60). Given the long-standing duration of
chronic headache activity by our patients, it is not sur-
prising that headache impact and depression did not re-
veal more marked changes, even at 1 year follow-up.
Changes of a psychological nature often take additional
time to fully manifest [26]. Anxiety scores remained un-
changed over time. Although anxiety disorders and CM
are known to be comorbid [64] – STAI scores revealed
the absence of significant anxiety problems in either
group, thus leaving little room for change (“basement”
or floor effect).
The proportion of patients achieving a 50% reduction
in headaches frequency (a measure commonly used to
evaluate “clinically significant improvements”) was simi-
lar at all time-points (at 12 months: 50% in the MT-
Group, 52.6% in the Med-Group), and the same was true
Table 3 Mixed within-between ANOVA results
Variable Main effects for time Main effect for group Interaction (Time X Group)
Wilks’ lambda P partial η2 F p Wilks' lambda p partial η2
Headaches frequency .43 < .001 .57 0.00 .959 .93 .453 .07
Medications intake .31 < .001 .69 0.04 .842 .83 .094 .17
HIT .67 .002 .34 0.02 .902 .76 .020 .24
MIDAS .43 < .001 .57 0.02 .902 .86 .141 .14
BDI-13 .49 < .001 .51 1.12 .297 .93 .475 .07
STAI-S .82 .064 .19 0.70 .408 .93 .481 .07
STAI-T .82 .068 .18 0.00 .952 .89 .246 .11
Table 4 Post-hoc comparisons across time for significant time
main effects
Variable M SD M diff P
Freq
Baseline (ref) 18.5 7.1
3-month 8.6 6.1 9.9 < .001
6-month 10.9 7.4 7.6 < .001
12-month 11.4 7.9 7.1 < .001
Medications intake
Baseline (ref) 16.6 5.3
3-month 8.4 6.6 8.2 < .001
6-month 9.9 6.1 6.7 < .001
12-month 9.5 5.1 7.1 < .001
MIDAS
Baseline (ref) 73.9 42.2
3-month 33.0 31.2 40.9 < .001
6-month 40.2 40.6 33.7 < .001
12-month 52.6 50.8 21.3 ns
BDI-13
Baseline (ref) 13.3 6.2
3-month 7.6 6.4 5.7 < .001
6-month 8.5 5.5 4.9 < .001
12-month 9.0 6.7 4.4 .001
Note: Only comparisons to baseline scores are presented in this table, as all
other pairwise comparisons were not statistically significant
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for the proportion of patients no longer meeting the CM
criteria (at 12 months: 65% in the MT-Group, 73.7% in
the Med-Group). Taken as a whole, our results suggest
that the longitudinal course of patients receiving
Mindfulness-based treatment, and who were instructed
to refrain from medical prophylaxis (which was verified
by the dairy records participants maintained throughout
the study), was overall very similar to that for patients
who were administered conventional medical prophy-
laxis, with few exceptions noted.
Our preliminary data extend the findings of Wells and
colleagues [40], whose mindfulness intervention was
focused on episodic migraine and reported more limited
findings. To our knowledge, only one previous study has
examined the utility of mindfulness-based treatments for
chronic forms of headache (CM or Tension-Type Head-
ache, with the distribution not being reported) wherein
mindfulness was also examined as an “add-on” ther-
apy and consisted of a host of other therapeutic com-
ponents, some derived from a mindfulness framework
but many derived from other theoretical models [41].
These investigators found significant differences be-
tween MBSR + pharmacoterapy and pharmacotherapy
alone with respect to perceived pain intensity and quality
of life. However, it is not clear if their treatment impacted
headache frequency, which is our primary measure and
the primary outcome recommended by the most recent
IHS clinical trial guidelines [65], or other outcome mea-
sures such as those that we included, i.e., use of acute
medications, disability burden and mood. The fact that
positive effects (although not always reaching significant
changes) were observed in our study for these varied mea-
sures in patients who received our brief mindfulness train-
ing alone (in the absence of prophylactic medications)
Fig. 2 Longitudinal course of headache frequency and consumption of medication. Note. Differences were always significant compared to
baseline; no differences were found between the Med-Group and the MT-Group at any time point
Table 5 Pairwise comparisons between time points of HIT for each treatment group
Group Comparisons Mean difference
(A-B)
SE p 95% CI of difference
Time A Time B LL UL
Mindfulness Baseline 3 M 3.25 1.56 .240 -1.10 7.60
6 M 4.55 2.21 .247 -1.58 10.68
12 M 0.80 1.73 .998 -4.00 5.60
3 M 6 M 1.30 1.87 .983 -3.91 6.51
12 M -2.45 1.81 .705 -7.48 2.58
6 M 12 M -3.75 1.43 .073 -7.73 0.23
Pharmacological Baseline 3 M 6.21 1.60 .003 1.75 10.67
6 M 4.32 2.26 .328 -1.97 10.60
12 M 5.42 1.77 .024 0.50 10.34
3 M 6 M -1.90 1.92 .910 -7.24 3.45
12 M -0.79 1.86 .999 -5.95 4.37
6 M 12 M 1.11 1.47 .974 -2.97 5.18
Note. Multiple comparisons were adjusted with Sidak correction
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suggests that mindfulness-based treatment may be com-
parable to standard pharmacological prophylaxis as far as
its global positive clinical improvement. However, the ab-
sence of random assignment and the fact that our study
was not cast as a non-inferiority trial leaves this possibility
more as a hypothesis, one in need of further testing.
Mood is one of the most important non-headache
factors associated with migraine chronification [7, 64]
and reducing headache frequency can lead to reductions
in depression [29, 66]. Nonetheless, the relevance of
depressive symptoms remains somewhat controversial.
In fact, in previous studies on CM-MO samples [24, 67]
depression scores – measured with the updated BDI-II
[68] and not with the original BDI – were not correlated
with frequency of headaches and, when implemented in
a predictive model together with headache frequency
and pain intensity, BDI-II scores had higher value in
predicting disability and quality of life scores. Our find-
ing that Mindfulness practice (as well as medication)
had a modest positive effect on levels of reported de-
pression over time is compatible with a conclusion pre-
viously drawn in studies addressing depression and
mindfulness-based treatments [69–73]. These findings
show that the effect of mindfulness-based approaches on
symptoms of depression were superior to psycho-
educational intervention and non-inferior to individual
cognitive behavioral therapy, that they yielded similar re-
sults compared to antidepressant therapies and, finally,
that the effect is maximized when the treatment is com-
bined. Considering that only 40% of patients in the
MED-group received a therapy having some kind of
mood-modulating effect, the finding that the impact on
mood component was similar is in line with the previous
report, and suggests that mindfulness-based treatments,
combined with appropriate antidepressant therapy,
might yield an increased impact on symptoms of
depression.
Although mean BDI values for both groups were in
the range of a significant levels of depression prior to
treatment, we hesitate to speculate further about the
meaningfulness of the changes reported here given that
our measure of depression is intended primarily as a
screening instrument and does not take the place of a
careful clinical diagnosis.
Fig. 3 Estimated marginal means for HIT-6 scores across time for Mindfulness and Pharmacology groups. Error bars represent standard errors
Table 6 Percent improvement and percent of patients no
longer meeting criteria for CM at each time-point
MT-Group Med-Group Chi-Squared
(P-value)
50% reduction 3 Months 57.1% 76.2% 1.71 (P = .190)
6 Months 47.6% 26.3% 1.93 (P = .165)
12 Months 50.0% 52.6% 0.03 (P = .869)
No longer CM 3 Months 95.2% 90.0% 0.41 (P = .520)
6 Months 76.2% 78.9% 0.04 (P = .835)
12 Months 65.0% 73.7% 0.35 (P = .557)
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More recent conceptions, wherein migraine is being
recognized as a condition in which biological, social and
psychological aspects are very interconnected [25] has
helped to increase awareness of the need to modify
therapeutic approaches to include newer and sometimes
“non-conventional” options (behaviorally and cognitively
based), along with “traditional” treatments (i.e., medical)
to better help patients to manage their condition, reduce
their medication intake, and minimize the incidences of
relapse in overuse after withdrawal [25, 74].
Mindfulness is designed to promote the ability to focus
on and accept the present situations and the difficulties
of every day. As demonstrated by Kabat-Zinn [75],
patients who have been educated to use mindfulness
may better manage stressful situations, increase their
self-efficacy, and learn to manage pain more adequately
avoiding the compulsion between pain and medication
intake which easily sets in motion the vicious cycle of
pain and medication and to the condition of overuse.
Mindfulness research, especially as regards headache, re-
mains in the infancy stage, with many aspects in need of
further investigation. Among these are determining
which of the myriad of bio-psycho-social factors may
underlie treatment effectiveness, including, for example,
changes in perception of and reactions to pain sensations
and emotion, self-efficacy and coping abilities, physiology,
cerebral structures and circuits [19, 38, 46, 47].
Although our findings are encouraging and suggestive
of the independent value of mindfulness for headache
care, certain design limitations preclude us making un-
equivocal claims. Our inability to randomize patients to
conditions serves as a limiting factor, with results per-
haps applying only to those particularly motivated to
commit to an extended training period for mindfulness.
Our headache center is designed primarily as a fee for
service clinic, where patient preferences must be consid-
ered. However, as pointed out by Nash et al [56] trials of
this type, more aptly termed “effectiveness trials” (versus
the more standard “efficacy trials”) clearly have a place
in the early stage of treatment development. In this case,
we hope our findings serve to expand recently published
data on patients with primary headaches supporting the
clinical value of mindfulness in the most severely
affected patients in the migraine spectrum; i.e., those
with chronic migraine coupled with medication overuse.
Another consideration is our inability to document the
extent to which patients adhered to each treatment (no
dose monitoring for the MED group and no checks for
amount of mindfulness practice or the depth of learning
patients acquired). Nonetheless, we believe our findings
support the value of conducting further more well-
controlled studies (incorporating random assignment,
larger samples sizes, and checks on integrity of treat-
ment) are warranted to more fully explore the benefits,
boundaries, and mechanisms of action for mindfulness
in treating chronic migraine by itself and when it is
complicated by medication overuse and medical or psy-
chological comorbidities. Finally, our sample was com-
posed of patients with CM and with no psychiatric
comorbidities. Two literature reviews showed that
migraineurs, compared to the general population, are
much more likely to suffer from psychiatric comorbidi-
ties (up to 60-70% for mood and anxiety disorders) and
that women with migraine with aura are at an increased
risk of suicide attempt [76, 77]. Conversely, the evi-
dence on the relationships between mood disorders
expression and suicidal ideation seems contrasting,
with some studies finding and others not finding any
connections [78, 79]. Patients included in our sample
seem to be clearly different from those described in
these previous studies, as they did not have psychi-
atric comorbidity – although some degree of low
mood was found – and actually we had no reasonable
ground to suspect any suicidal ideation among the
participants herein included. Caution is therefore
recommended before generalizing our results to the
entire population of CM patients: for all of the above
reasons, our results should be taken as preliminary.
Conclusions
Our results provide initial support for the beneficial effect
of Mindfulness-based treatment in the management of
chronic migraine that is accompanied with medication
overuse, a headache form which represents a clinical chal-
lenge. Our results further suggest that a Mindfulness-based
treatment may be comparable to standard pharmacological
prophylaxis with regard to relevant primary outcomes such
as headaches frequency reduction and reduction in the
consumption of acute medications.
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